Genentech, Idec, Zenyaku Kogyo deal

IDPH and GNE extended their March agreement to develop IDEC-C2B8 for B-cell lymphoma, under which GNE receives the right to develop, market and sell the compound in Japan and other Asian countries in addition to previously granted rights to other markets outside the U.S. and Canada.

The companies, which share rights in the U.S. and Canada, are developing IDEC-C2B8 as a single agent to treat relapsed low-grade or follicular non-Hodgkin's lymphomas. ...